A5010982066- Virus-based gene therapy research
- CAR-T cell therapy research
- Glycosylation and Glycoproteins Research
- Acute Lymphoblastic Leukemia research
- Monoclonal and Polyclonal Antibodies Research
- Nanowire Synthesis and Applications
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Epigenetics and DNA Methylation
- Immunotherapy and Immune Responses
- RNA modifications and cancer
- Histone Deacetylase Inhibitors Research
Université Claude Bernard Lyon 1
2024
Centre National de la Recherche Scientifique
2024
Centre Léon Bérard
2024
Centre de Recherche en Cancérologie de Lyon
2021-2024
Inserm
2024
University of Southern California
2018
Synthetic glucocorticoids (GCs) are used to treat lymphoid cancers, but many patients develop resistance treatment, especially GC. By identifying genes that influence sensitivity GC-induced cell death, we found histone methyltransferases G9a and G9a-like protein (GLP), two glucocorticoid receptor (GR) coactivators, required for death in acute lymphoblastic leukemia (B-ALL) line Nalm6. We previously established a few selected automethylated GLP recruit heterochromatin 1γ (HP1γ) as another...
Abstract Cancer cells rely on alternative modes of translation for protein synthesis, promoting internal ribosome entry site (IRES)-dependent mRNA encoding pro-oncogenic factors. Furthermore, ribosomes translate with lower fidelity in tumor cells. We proposed that these translational modifications cancer produce shared tumor-specific epitopes derived from IRES-containing oncogenes. To identify such neoepitopes, we developed an silico -based method applied to c-MYC . showed the non-canonical...
BCR pathway inhibitors idelalisib and ibrutinib were the first small molecule targeted agents for B-cell malignancies. In spite of encouraging response rates in various forms B cell diseases, patients will eventually develop relapse due to emergence resistant cells. To better identify possible mechanisms resistance we developed characterized idelalisib- ibrutinib-resistant variants human non Hodgkin’s lymphoma lines DoHH2 Daudi. These displayed a cross-resistance profile limited PI3K...